293 related articles for article (PubMed ID: 24778277)
1. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Gulley JL; Madan RA; Tsang KY; Jochems C; Marté JL; Farsaci B; Tucker JA; Hodge JW; Liewehr DJ; Steinberg SM; Heery CR; Schlom J
Cancer Immunol Res; 2014 Feb; 2(2):133-41. PubMed ID: 24778277
[TBL] [Abstract][Full Text] [Related]
2. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
[TBL] [Abstract][Full Text] [Related]
3. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Farsaci B; Jochems C; Grenga I; Donahue RN; Tucker JA; Pinto PA; Merino MJ; Heery CR; Madan RA; Gulley JL; Schlom J
Int J Cancer; 2014 Aug; 135(4):862-70. PubMed ID: 24474335
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Gulley JL; Heery CR; Madan RA; Walter BA; Merino MJ; Dahut WL; Tsang KY; Schlom J; Pinto PA
Cancer Immunol Immunother; 2013 Sep; 62(9):1521-31. PubMed ID: 23836412
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
[TBL] [Abstract][Full Text] [Related]
7. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
Nesslinger NJ; Ng A; Tsang KY; Ferrara T; Schlom J; Gulley JL; Nelson BH
Clin Cancer Res; 2010 Aug; 16(15):4046-56. PubMed ID: 20562209
[TBL] [Abstract][Full Text] [Related]
8. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.
Sanda MG; Smith DC; Charles LG; Hwang C; Pienta KJ; Schlom J; Milenic D; Panicali D; Montie JE
Urology; 1999 Feb; 53(2):260-6. PubMed ID: 9933036
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer vaccines in clinical trials.
Lubaroff DM
Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
[TBL] [Abstract][Full Text] [Related]
12. Vaccine immunotherapy for prostate cancer: from mice to men.
Lubaroff DM; Vaena D; Brown JA; Zehr P; Griffith KC; Brown E; Eastman J; Nepple K; Kattula A; Williams RD
Immunol Res; 2014 Aug; 59(1-3):229-35. PubMed ID: 24847764
[TBL] [Abstract][Full Text] [Related]
13. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
14. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Jochems C; Tucker JA; Tsang KY; Madan RA; Dahut WL; Liewehr DJ; Steinberg SM; Gulley JL; Schlom J
Cancer Immunol Immunother; 2014 Apr; 63(4):407-18. PubMed ID: 24514956
[TBL] [Abstract][Full Text] [Related]
15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS
Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041
[TBL] [Abstract][Full Text] [Related]
18. Serum antibodies to blood group A predict survival on PROSTVAC-VF.
Campbell CT; Gulley JL; Oyelaran O; Hodge JW; Schlom J; Gildersleeve JC
Clin Cancer Res; 2013 Mar; 19(5):1290-9. PubMed ID: 23362327
[TBL] [Abstract][Full Text] [Related]
19. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Madan RA; Arlen PM; Mohebtash M; Hodge JW; Gulley JL
Expert Opin Investig Drugs; 2009 Jul; 18(7):1001-11. PubMed ID: 19548854
[TBL] [Abstract][Full Text] [Related]
20. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]